Table 4.
Ten-Year Cumulative Incidence, Absolute Risk Differences, and HRs for Incident HCC and All-Cause Mortality in the Unmatched Study Population, by Statin Type and cDDDs (n = 63 279)
| Variable* | Statin Use† |
P Value for Trend‡ | |||
|---|---|---|---|---|---|
| None | 30–299 cDDDs | 300–599 cDDDs | ≥600 cDDDs | ||
| Lipophilic statin use§ | |||||
| HCC | |||||
| Cumulative incidence (95% CI), % | 8.4 (7.8 to 9.0) | 5.0 (4.4 to 5.6) | 3.8 (3.3 to 4.3) | 2.5 (1.6 to 3.4) | |
| Absolute risk difference (95% CI), percentage points|| | 0 (reference) | −3.4 (−4.6 to −2.2) | −4.6 (−6.3 to −2.9) | −5.9 (−7.6 to −4.2) | |
| HR (95% CI) | 1 (reference) | 0.75 (0.62 to 0.93) | 0.52 (0.40 to 0.67) | 0.41 (0.32 to 0.61) | <0.001 |
| Death | |||||
| Cumulative incidence (95% CI), % | 15.1 (14.5 to 15.6) | 8.0 (7.3 to 8.8) | 7.9 (7.1 to 8.8) | 5.5 (5.0 to 6.0) | |
| Absolute risk difference (95% CI), percentage points|| | 0 (reference) | −7.1 (−8.3 to −5.9) | −7.2 (−8.5 to −6.0) | −9.6 (−11.2 to −8.1) | |
| HR (95% CI) | 1 (reference) | 0.79 (0.64 to 0.95) | 0.79 (0.64 to 0.94) | 0.58 (0.48 to 0.72) | 0.001 |
| Hydrophilic statin use¶ | |||||
| HCC | |||||
| Cumulative incidence (95% CI), % | 8.1 (7.9 to 8.8) | 7.0 (6.4 to 7.9) | 6.4 (5.7 to 7.1) | 6.5 (5.8 to 7.5) | |
| Absolute risk difference (95% CI), percentage points|| | 0 (reference) | −1.1 (−2.7 to 0.5) | −1.7 (−3.6 to 0.3) | −1.6 (−3.4 to 0.2) | |
| HR (95% CI) | 1 (reference) | 0.97 (0.89 to 1.06) | 0.92 (0.81 to 1.05) | 0.94 (0.82 to 1.03) | 0.60 |
| Death | |||||
| Cumulative incidence (95% CI), % | 15.9 (15.6 to 16.2) | 13.5 (13.1 to 13.9) | 10.6 (10.3 to 11.0) | 11.8 (11.1 to 12.5) | |
| Absolute risk difference (95% CI), percentage points|| | 0 (reference) | −2.4 (−3.5 to −1.3) | −5.3 (−6.4 to −4.2) | −4.1 (−5.5 to −2.7) | |
| HR (95% CI) | 1 (reference) | 0.92 (0.84 to 0.98) | 0.85 (0.79 to 0.91) | 0.88 (0.82 to 0.95) | 0.38 |
cDDD = cumulative defined daily dose; HBV = hepatitis B virus; HCC = hepatocellular carcinoma; HCV = hepatitis C virus; HR = subdistribution hazard ratio.
Cumulative incidence, risk differences, and HRs were estimated using a proportional hazards regression model that was fitted to the unmatched population, accounted for competing risks, and was stratified by cohort (HBV vs. HCV) and quintile of propensity score.
Defined as ≥30 cDDDs of filled statin prescriptions and modeled as a time-varying exposure updated at each month of follow-up.
P value for linear trend in the subdistribution hazards models was calculated using continuous cDDDs.
Atorvastatin and/or simvastatin.
95% CI was calculated via bootstrapping.
Rosuvastatin and/or pravastatin.